Cerebellar Metaplasticity in the Swallowing Motor System
Launched by UNIVERSITY OF MANCHESTER · Dec 3, 2024
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach to help improve swallowing difficulties, known as dysphagia, which can be a serious problem for many people, especially after strokes. The researchers want to see if a technique called cerebellar repetitive transcranial magnetic stimulation (Cer-rTMS) can change how the brain controls swallowing. This method is non-invasive, meaning it doesn’t require surgery, and is thought to be safer than other brain stimulation methods. The goal is to find a more effective treatment for people who have trouble swallowing by seeing if this new technique can lead to better brain responses and swallowing behavior.
To participate in this study, individuals must be healthy adults over 18 years old. However, there are certain conditions that would exclude someone from joining, such as having a history of seizures, a cardiac pacemaker, past brain surgery, or any previous swallowing issues. During the trial, participants will experience stimulation to specific areas of the brain while the researchers observe how it affects swallowing. This study is not yet recruiting, but it aims to provide valuable insights into improving treatment for dysphagia in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy participants \> 18 years of age
- Exclusion Criteria:
- Exclusion criteria will be the presence or a history of:
- • 1. Epilepsy
- • 2. Cardiac pacemaker
- • 3. Previous brain surgery
- • 4. Previous swallowing problems
- • 5. The use of medication which acts on the central nervous system
- • 6. Any implanted metal in the head
- • 7. Pregnancy (self-declared)
About University Of Manchester
The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ayodele Sasegbon
Principal Investigator
University of Manchester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported